跳至主要内容
临床试验/NL-OMON51330
NL-OMON51330已完成不适用

A pilot study to assess the safety and feasibility of fluorescent sentinel lymph node identification in colon carcinoma using submucosal bevacizumab-800CW - IBIZA-1(pilot)

Meander Medisch Centrum0 个研究点目标入组 5 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
5

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Oral and written informed consent (IC)
  • - Aged 18 years and older
  • - Pathologically confinmed and/or suspected cT1-3N0-2M0 colon carcinoma

排除标准

  • - Distant metastasis
  • - Suspicion of cT4 disease based on pre-operative assessment
  • - Metastatic or T4 disease discovered during intraoperative staging
  • - Pregnancy, lactation or a planned pregnancy during the course of the
  • - Previous colon surgery, excluding appendectomy.
  • - Contra-indication for laparoscopic/robotic surgery
  • - Inadequately controlled hypertension with or without current antihypertensive
  • medication.
  • - Within 6 months prior to inclusion: myocardial infarction, TIA, CVA,
  • pulmonary embolism, unstable angina pectoris, or uncontrolled chronic hepatic
  • - Regarding bevacizumab: Hypersensitivity to Chinese Hamster Ovary
  • (CHO) cell products or other recombinant human or humanised
  • antibodies. Or an allergy for its components (Trehalose dehydrate,
  • sodium phosphate, polysorbate 20, water for injections)

研究者

发起方
Meander Medisch Centrum

相似试验